P21: brain-boosting peptide derived from a nerve-growth protein (CNTF)
A small peptide derived from a nerve-support protein that promotes new brain-cell growth and improves memory in animal studies; experimental, not yet an approved drug.
- Class
- CNTF-derived neurotrophic peptide
- Status
- Research compound — no approved therapeutic use; not in published human clinical trials
- Best-supported effect
- Improved cognition and hippocampal neurogenesis in Alzheimer's disease and tauopathy mouse models (preclinical)
- Main caveat
- No human pharmacokinetic, safety, or efficacy data published; evidence is concentrated in a single originating research program with sparse independent replication
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Snapshot
Class: CNTF-derived neurotrophic peptide
Evidence tier: Animal-only evidence
Status: Research compound — no approved therapeutic use; not in published human clinical trials
Best-supported effect: Improved cognition and hippocampal neurogenesis in Alzheimer's disease and tauopathy mouse models (preclinical)
Main caveat: No human pharmacokinetic, safety, or efficacy data published; evidence is concentrated in a single originating research program
What this is
P21 (also written P021) is an 11-amino-acid peptide derived from ciliary neurotrophic factor (CNTF). It was designed by the Iqbal laboratory at the New York State Institute for Basic Research in Developmental Disabilities to capture the pro-neurogenic and procognitive activity of CNTF in a small molecule capable of crossing the blood-brain barrier. A key chemical modification — adamantylation of a glycine residue — was incorporated to support BBB penetration and proteolytic stability while eliminating the anorectic hypothalamic effects that had derailed full-length CNTF clinical development.
P21 should not be confused with the unrelated p21/CIP1/WAF1 cell-cycle inhibitor protein, a 165-amino-acid intracellular protein central to senescence biology. They share a casual name and nothing else.
Evidence map
| Evidence layer | Grade | What it supports |
|---|---|---|
| Human | None | No published human trial data of any phase is identified |
| Animal | Moderate | Improved cognition, reduced tau hyperphosphorylation, and increased dentate gyrus neurogenesis in AD and tauopathy mouse models; additional work in CDKL5 deficiency and TBI rodent models |
| In vitro | Weak | In vitro work reported alongside the CDKL5 deficiency study; limited independently characterized cell-assay data |
| Computational | None | No computational or docking data identified |
| Mechanism | Plausible | CNTF biology and LIF–neurogenesis axis are established; P21-specific mechanistic characterization is incomplete and primarily from the originating group |
Note: The published evidence base is concentrated in the originating Iqbal-lab research program. Independent replication is sparse and represents a key limitation of the current evidence base.
Claim check
| Claim | Verdict | Evidence layer | Confidence |
|---|---|---|---|
| Promotes hippocampal neurogenesis | Supported (preclinical) | Animal | Medium — multiple studies from one lab; sparse independent replication |
| Improves cognition in Alzheimer's disease models | Supported (preclinical) | Animal | Medium — consistent within originating program; no independent replications confirmed |
| Reduces tau hyperphosphorylation in tauopathy models | Supported (preclinical) | Animal | Medium — observed in AD and tauopathy mouse models; mechanism plausible |
| Effective for Alzheimer's disease in humans | Not established | Human | High — no human trial of any phase has been published |
| Safe for human use | Not established | Human | High — no human pharmacokinetic, tolerability, or safety data published |
| Avoids the anorectic side effects of full-length CNTF | Supported (preclinical) | Animal | Medium — STAT3 hypothalamic activation not observed in animal models; human translation not established |
| P21 is currently in clinical trials | Contradicted | Human | High — published literature explicitly states no published Phase I, II, or III trial exists |
Experimental exposure
This section reports exposure used in animal experiments. It does not establish human dosing.
| Context | System | Experimental exposure | Duration | Endpoint | Limitation |
|---|---|---|---|---|---|
| Animal experiment | Mouse models (Alzheimer's disease, tauopathy) | Intraperitoneal injection, typically 50–100 nmol per mouse per day | Weeks to several months of continuous dosing | Cognition, dentate gyrus neurogenesis, tau hyperphosphorylation | IP route is not used for chronic human dosing; no human pharmacokinetic equivalence established |
| Animal experiment | Rodent CDKL5 deficiency model | In vitro and in vivo exposure per study protocol | Study-specific duration | Neurogenesis and functional endpoints | Source does not provide exact regimen; details not individually extracted |
| Animal experiment | Rodent TBI model | Study-specific protocol; exact regimen not individually extracted | Weeks | Memory and neurogenesis markers | No human TBI trial conducted |
Preclinical safety signals
| Signal | System | Notes |
|---|---|---|
| Generally well-tolerated in reported animal studies | Rodent models | Per available sources, no major adverse effects in short animal protocols; chronic safety characterization is absent |
| Theoretical tumorigenicity risk from sustained neurogenesis augmentation | Preclinical rationale | Neural progenitor proliferation in CNS malignancy settings is a theoretical concern; not tested in long-duration studies |
| Theoretical seizure susceptibility interaction | Preclinical rationale | Neurogenesis modulators have complex relationships with epileptogenesis in animal models; no long-duration safety data |
| No reproductive or developmental toxicology data | Not characterized | No pregnancy, lactation, or pediatric safety data; mechanistic concern for fetal CNS development given P21's neurogenic activity |
| Long-term human safety | Not established | No chronic human safety data of any kind are identified |
Regulatory status
| Region / body | Status | Notes |
|---|---|---|
| US (FDA) | Not approved | P21 has no approved indication; not a controlled substance; not a recognized dietary supplement ingredient; not legitimately compoundable as a medication under current status; sold only as a research chemical |
| EU (EMA) / UK (MHRA) | Not approved | No marketing authorization identified in attached source |
| Canada (Health Canada) | Not approved | No marketing authorization identified in attached source |
| Australia (TGA) | Not approved | No marketing authorization identified in attached source |
| WADA | per available sources as not explicitly named on Prohibited List; S0 clause arguably applies | Source notes P21 is not currently named on the WADA Prohibited List, but states the S0 "non-approved substances" clause likely applies because P21 has no approved human therapeutic use anywhere; current list status not independently refreshed in this card |
No approved therapeutic status identified. This card describes a preclinical research compound, not an approved medicine.
Mechanism
P21 is derived from a biologically active region of ciliary neurotrophic factor (CNTF), incorporating residues corresponding to the 148–151 region of CNTF with adamantylation of a glycine residue. The adamantane group was introduced to support blood-brain barrier penetration and resistance to proteolytic degradation.
The proposed primary mechanism is competitive inhibition of leukemia inhibitory factor (LIF) signaling. LIF normally suppresses adult neurogenesis; disinhibiting this pathway promotes neural progenitor cell proliferation and differentiation in the dentate gyrus of the hippocampus. Downstream effects observed in animal models include increased BDNF expression and reduced tau hyperphosphorylation. Critically, unlike full-length CNTF, P21 is reported not to activate STAT3 signaling in the hypothalamus — an action of CNTF that caused pronounced anorectic effects that ended full-length CNTF clinical trials for ALS and obesity.
The proposed target (LIF receptor complex / CNTF receptor axis) is inferred from the peptide's structural origin and behavioral animal-model data. Direct binding and receptor-occupancy data in human tissue are not characterized in the attached source. Mechanistic confidence is assessed as plausible but not verified at a human-relevant level.
Chemistry
| Field | Value |
|---|---|
| Amino-acid chain | 11-mer derived from CNTF; exact full sequence not individually extracted in attached source |
| Length | 11 amino acids |
| Topology | Linear |
| Key modification | Adamantylated glycine — incorporated at a position within the active-region sequence to support BBB penetration and proteolytic stability |
| Parent molecule | Ciliary neurotrophic factor (CNTF), residues ~148–151 active region |
| Molecular weight | Not extracted from attached source |
| Formula | Not extracted from attached source |
| CAS | Not extracted from attached source |
| Sequence confidence | Needs review — exact sequence and modification position not individually extracted; source provides structural description only |
Open questions
- Human safety and tolerability: No published Phase I, II, or III human trial has been conducted. The human pharmacokinetic profile, dose-response, tolerability, and any efficacy signal remain entirely unknown.
- Independent preclinical replication: Most published findings originate from the Iqbal-lab research program. Reproduction in independent laboratories would substantially strengthen confidence in reported effect sizes and mechanism.
- BBB penetration in humans: The adamantane modification supports BBB penetration in rodent models. Whether adequate CNS exposure is achieved via subcutaneous or intranasal routes in humans has not been established.
- Long-term neurogenesis safety: Sustained augmentation of neural progenitor proliferation raises theoretical concerns regarding tumorigenicity, ectopic neurogenesis, and seizure susceptibility. No long-duration chronic safety studies are identified in the attached source.
- Efficacy in healthy adults: All preclinical work targets disease models (AD, tauopathy, TBI, CDKL5 deficiency). Whether P21 produces measurable cognitive effects in healthy individuals is untested.
- Exact sequence and chemistry confirmation: The full amino-acid sequence and exact modification position are not individually extracted in the available literature; verification against primary chemistry publications is needed before a confirmed sequence can be identified.
- Route-specific human exposure: Animal experiments used intraperitoneal injection. Subcutaneous injection and intranasal delivery are mentioned as practical human routes, but route-comparative bioavailability in humans is uncharacterized.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could a peptide being studied for Alzheimer's also help children with CDKL5-deficiency disorder, a rare genetic disease that causes severe epilepsy and developmental delay?
Children with CDKL5-deficiency disorder have very few treatment options and no approved cure. If P21 can restore normal nerve cell development in this disease, it could offer the first real chance at slowing or reversing the developmental damage, changing the lives of affected families.
Does this peptide fight Alzheimer's-linked protein tangles by reactivating the brain's own cleaning enzyme, rather than by blocking the enzyme that creates the tangles?
Most Alzheimer's drugs have tried to block tangle formation; almost all have failed. A drug that restores the brain's existing cleanup machinery would be a fundamentally different approach, potentially working even in patients where the disease is already advanced.
Does the chemical group added to P21 to cross the blood-brain barrier also force the peptide into the precise shape needed to activate its target?
If the modification serves two essential roles simultaneously, it would explain why P21 works when simpler versions of the CNTF protein do not, and would teach drug designers a reusable trick for making other short neurotrophic peptides both brain-penetrant and biologically active.
Does this brain-boosting peptide activate only the beneficial part of the nerve-growth receptor, while leaving alone the part that caused unwanted weight loss in previous trials?
If confirmed, this insight would explain why P21 is safer than the original CNTF protein and provide a blueprint for engineering other neurotrophic drugs that preserve brain benefits without causing metabolic side effects.
Could removing or replacing the cysteine at the end of this brain-protective peptide make it more stable and easier to manufacture, without making it less effective?
Manufacturing stable peptide drugs is expensive and difficult. Eliminating the problematic cysteine, if it does not affect activity, would make P21 significantly easier and cheaper to produce, accelerating its path to clinical trials and eventual patient access.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.39271119236946106 | openfold3-mlx |
| ranking score | 0.5500988364219666 | openfold3-mlx |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.702 | global PDE — lower = better |
| disorder | 0.165 | fraction disordered |
| chain pair ipTM (A, B) | 0.393 | interface quality |
▸3-letter notation
▸recipeopenfold3-mlx 0.3.1
| parameter | value |
|---|---|
| model | openfold3-mlx 0.3.1 |
| weights | — |
| hardware | — |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | — |
| diffusion samples | 1 |
| runtime | 92s |
| predicted by | mlx@peptide |
| predicted at | 2026-05-03 |
▸citationbibtex
@peptide{pep10929,
sequence = {VKQISNKLTEFISQIEHIRETNSDC},
target = {neuroprotective},
author = {peptidemodel},
year = {2026},
status = {computed}
}